Table 3.
Characteristics of the breakthrough infection in the study population (N = 98).
| N (%) | |
|---|---|
| Contact with confirmed COVID-19 case | 57 (57.6) |
| Time length from testing positive to negative (in days) * | 11.0 ± 3.6 |
| COVID-19 symptoms | |
| At least one | 79 (80.6) |
| Nasal congestion or runny nose | 35 (35.7) |
| Muscle/joint or body pains | 34 (34.7) |
| Fever/chills | 33 (33.7) |
| Cough | 31 (31.6) |
| Sore throat | 25 (25.5) |
| Headache | 20 (20.4) |
| Shortness of breath or difficulty in breathing | 10 (10.2) |
| Asthenia/fatigue/weakness | 8 (8.2) |
| Ageusia (loss of sense of taste) | 6 (6.1) |
| Anosmia (loss of smell) | 6 (6.1) |
| Tachyarrhythmia | 2 (2.0) |
| Vertigo | 2 (2.0) |
| Neuralgia | 1 (1.0) |
| Use of medication § | |
| At least one | 51 (53.1) |
| Paracetamol | 22 (22.9) |
| Non-steroidal anti-inflammatory drug | 9 (9.4) |
| Prednisone | 14 (14.6) |
| Betamethasone | 2 (2.1) |
| Dexamethasone | 1 (1.0) |
| Unknown glucocorticosteroid | 4 (4.2) |
| Azithromycin | 15 (15.6) |
| Amoxicillin/clavulanic acid | 3 (3.1) |
| Clarithromycin | 1 (1.0) |
| Unknown antibiotic | 5 (5.2) |
| Bromhexine | 1 (1.0) |
| Oxymetazoline | 1 (1.0) |
| C and/or D vitamin supplement | 21 (21.9) |
| Lactoferrin | 2 (2.1) |
* Summarized by mean ± standard deviation (SD). § Percentage was calculated on 96 observations due to missing data.